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ABSTRACT 
Protein kinase CK2 plays major roles in multiple biological processes, as has been 
reported in literature. Phosphoproteomic and bioinformatics data suggests that CK2 is 
involved in many cellular pathways however there is no report published on the unbiased 
global validation of its bona fine cellular substrates and how the CK2 dependent 
phosphorylation is modulating these pathways. Therefore, there is a need for methods that 
can do this validation process. Since the kinases have similar nature to phosphorylate their 
substrates, it is a great challenge to find or validate new substrates of a targeted kinase. In 
this study, a chemical genetics approach was used when the phenylalanine bulky residues 
were identified in CK2α as F113 and CK2α’ as F114. These residues were mutated to 
glycine to expand the ATP binding pocket, and create an analogues sensitive kinase which 
can utilize an ATP analogue nucleotide. The substitution did not alter the activity or 
specificity of the kinase. Furthermore, the analogue sensitive-CK2 (as-CK2) and wild 
type-CK2 (wt-CK2) α and α’ SILAC labeled stable cell lines were generated, then 
thiophosphrylation reactions were done using N6-(2-phenylethyl) ATPγS (2peATPγS) to 
label substrates in the cell lines. The thiopeptides were identified using mass spectrometry 
based proteomics approach. The thiopeptides found only in as-CK2 compared to control 
were considered as CK2 substrates. Our results highlight the potential of using analog-
sensitive CK2 to further expand our knowledge of the cellular roles of CK2 and elucidate 
kinase-substrate relationships. 
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CHAPTER ONE: INTRODUCTION 
1.1 General Introduction 
Protein Kinases are the enzymes which catalyze phosphorylation of cellular proteins by 
transfer of gamma phosphoryl group from ATP or GTP to hydroxyl group of serine, 
threonine or tyrosine residues of these substrates to regulate the cellular processes 
(Hunter, 2000; Manning et al 2002). Phosphorylation activates downstream cellular 
signaling pathways and, in this way, it can affect key signal transduction pathways leading 
to cell survival, apoptosis or cell proliferation (Cohen, 2000). Data from the literature 
suggest that in human proteome there might be approximately 700,000 potential 
phosphorylation sites (Ubersax and Ferrell 2007). Actually, this post-translational protein 
modification event is very common in in vivo cell function. The crucial role of kinases in 
signaling pathways is demonstrated since any alteration or dysregulation in their activity 
leads to the onset of several diseases and cancer (Brognard and Hunter, 2011). 
 1.2 Casein Kinase2 (CK2) protein kinase 
CK2 protein is a pleiotropic serione/threonine kinase, which exists in a tetrameric 
holoenzyme form, composed of two catalytic subunits CK2α and CK2α’ (coded by 
CSNK2A1 and CSNK2A2 genes, respectively) and two regulatory subunits CK2β (coded 
by CSNK2B gene). The catalytic subunits have constitutive activity also in the absence 
of the regulatory units, the regulatory CK2β subunits play an important role in the 
assembly of CK2 complexes, in enhancing the catalytic activity and stability of CK2, and 
in its substrate selectivity.  (Poletto et al, 2008; Litchfield, 2003). The bioinformatics 
studies suggest that the 20% of the phosphoproteome might be the direct substrates of 
CK2 kinase. (Salvi et al., 2009). Based on the bioinformatic and systematic studies its 
known that the minimum consensus recognition motif of CK2 is Ser-Xaa-Xaa-Acidic, 
where the acidic residue may be Glu, Asp, pSer or pTyr (Meggio and Pinna 2003). CK2 
is involved in multiple biological processes such as cell proliferation, cell survival or 
death (St-Denis and Litchfield, 2009), as well as it affects several biological pathways 
modulating protein stability and degradation (Niechi et al 2015; Scaglioni et al 2008), 
transcription and translation (Cabrejos et al 2004; Gandin et al 2016), and circadian 
rhythms (Tsuchiya et al 2009) (Figure 1). Moreover, it has been known that deregulation 
of CK2 could lead tumor progression in different types of cancer (Trembley et al 2009). 
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Figure 1: Involvement of CK2 in different pathways (Rabalski et al, 2016) 
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1.2.1 CK2 structure 
 
As previously described, CK2 kinase is an heterotetrametric protein, consisting of two 
catalytic units α (42 kDa) and α’ (38 kDa) and two regulatory β subunits (28 kDa) (Figure 
2).  Different heterotetramers, such as α2β2, or αα′β2, or α′2β2 could be found (Grahem and 
Litchfield, 2000). The CK2 kinase has a smaller active site which is due to the presence 
of two bulky residues Ile74 and val66 compared to alanine residue which is present in 
other kinases (Sarno et al, 2005). This peculiar active site also enables the CK2 kinase to 
utilize ATP and as well as GTP compared to other kinases (Niefind et al, 1999). The 
crystal structure of tetramer reveals that one of the catalytic subunit might bind to a non-
hydrolysable ATP analogue (adenosine 5«-[β,γ-imido]triphosphate, AMPPNP), as well 
as ATP in the catalytic site (Lolli et al, 2012). CK2β regulatory subunit consists of 
autophosphorylation sites, which include Ser2, Ser3 and Ser4. An additional Ser209 site 
is present, which is phosphorylated in cell cycle dependent manner (Litchfield et al, 1991). 
Furthermore, CK2β consists of regions/domains (Figure 3), a domain similar to the 
sequence of destruction box (Arg47–Asp55) is believed to be involved in the stability of 
CK2β (Zhang et al, 2002), whereas, CK2β consists of acidic loop (Asp55–Asp64), which 
is involved in polyamine binding to regulate CK2 activity (Boldyreff et al, 1994; Leroy 
et al, 1997). The crystal structure of a dimeric form of the regulatory β subunit 
demonstrated that interaction between two CK2β subunits is mediated by a zinc finger 
composed of four conserved cysteine residues: Cys109, Cys114, Cys137 and Cys140 
(Canton et al, 2001). In tetrameric structure of CK2 kinase, the β subunits, without having 
contact with each other, form a stable dimer linking the two catalytic subunits. Anyway, 
each of the catalytic subunit interacts with both the C-terminal tail of the regulatory β 
subunits, in which the interaction occurs between the Asn181–Ala203, present in the 
CK2α subunit, and the Arg186–Gln198 residues of the regulatory CK2β domain (Niefind 
et al, 2001). 
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Figure 2: Ribbon diagram of tetrameric structure of CK2 kinase (Nienberg et al, 2016) 
 
 
 
Figure 3: Sequence domains of CK2 β (Litchfield, 2003) 
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In majority of kinases, there is an Asp-Phe-Gly (DFG) motif in the activation loop of the 
N-terminus. When the kinase is active, phenylalanine of DFG forms a hydrophobic spine 
with N-terminal and another with C-terminal lobe residue, this conformation is called the 
“DFG-in” (Treiber and Shah, 2013). The inactivation of the kinases is due to the alteration 
of interaction of asparate and glycine with in DFG. This alteration is caused by the 
movement of phenylalanine out of hydrophobic pocket as a result blocking ATP binding 
to the active site (Treiber and Shah, 2013). CK2 is a unique kinase as in its primary 
sequence a tryptophan is included at position 176 instead of phenylalanine. Tryptophan 
causes the C and N-terminal lopes to be in an arrangement so that the essential residues 
in the active sites are properly positioned leading CK2 to be constitutively active (Vijayan 
et al, 2015). 
1.3 CK2 Involvement in Cancer 
 
Protein CK2 kinase has been shown to have elevated activity in many types of cancers 
such as lung (Daya-Makin et al, 1994), breast (Landesman-Bollag et al, 2001), head and 
neck (Faust et al, 2000) and prostate cancer (Yenice et al, 1994). CK2 is present 
ubiquitously in all cell types but normal cells compared to cancer cells have different 
localization of CK2. If in normal cells it is localized in a diffused pattern both in the 
nucleus and cytoplasm, in cancer cells nuclear compartment has higher level of CK2 
kinase compared to cytoplasm (Faust et al, 1999; Laramas et al, 2007). In this context it 
should be note that CK2 kinase is involved in the regulation and stability of tumor 
suppresser proteins and oncoproteins, the dysregulation of these might lead to tumor 
formation and progression (Duncan and Litchfield, 2008).  
1.3.1 CK2 regulation of Tumor suppressor proteins and oncogenic proteins 
 
The tumor suppressor proteins are the gatekeepers of cell cycle, an important part in the 
cell signaling pathways. The dysregulation of activity or loss of function of the tumor 
suppressor protein has been associated with many types of cancers (Hanahan and 
Weinberg, 2000). CK2 kinase is believed to be involved in the regulation of these anti-
tumoral proteins, the phosphorylation of which increases or decreases their activity and 
protects or promotes their degradation (Torres and Pulido, 2001; Keller and Lu, 2002). 
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One of the essential and well-known example of tumor suppressor protein is p53, which 
has been known to regulate cell cycle, differentiation and apoptosis (Oliveira et al; 2005 
During DNA damage response, CK2 forms a complex with the chromatin transcriptional 
elongation factor, a heterodimer of both the suppressor of Ty 16 (hSPT16) and the 
structure specific recognition protein 1 (SSRP1). When hSPT16 and SSRP1 are 
complexed with CK2, they change the substrate specificity of CK2 to phosphorylate p53 
over the other tested substrates. (Keller and Lu, 2002). The phosphorylation of Ser392 
residue of p53 results in an increase of both DNA binding and transcriptional activity of 
this tumor suppressor protein (Kapoor and Lozano, 1998). CK2 kinase has shown to 
phosphorylate SSRP1 also, suggesting that CK2 regulates the DNA-binding ability of 
SSRP1 and so that this regulation may be responsive to the inhibition of transcription and 
replication after DNA damage (Li et al; 2005).  
CK2 kinase is involved in regulation of different signaling pathways also involved in 
cancer, which include JAKs/STATs (Zheng et al, 2011), Wnt and NF-κB signaling 
(Dominguez et al, 2009), as well as PTEN/PI3K/Akt-PKB (Miller et al, 2002) and 
Hedgehog signaling (Hh) (Jia et al, 2010). CK2 involvement in few pathways are 
discussed below. 
1.3.2 CK2 involvement in Akt pathway  
 
CK2 kinase has been to be involved in PI3K/Akt signal transduction pathway. The Akt 
pathway supports cell cycle progression, cellular growth and cell survival (Vara et al, 
2004). Akt1 is phosphorylated at Thr308 and Ser473 residue to make it active, but an 
additional phosphorylation of Ser129 residue by CK2 kinase is believed to make Akt a 
constitutively active kinase (Di Maira et al, 2005). The phosphorylation of Ser129 residue 
is known to, stabilize the association of Akt with chaperone Hsp90 which protects Akt 
against the dephosphorylation of Thr308 done by protein phosphatase 2A (PP2A) (Sato 
et al, 2000; Di Maira et al 2009). It is also shown that phosphorylation at Ser129 promotes 
upregulation of β-catenin pathway, to increase β-catenin transcriptional activity (Ponce 
et al, 2011). CK2 kinase involvement in Akt pathway is also evident from its inhibitory 
effect on phosphatase and tensin homolog (PTEN), a well-known tumor suppressor 
protein. PTEN is an integral part to keep check on the Akt pathway by inhibiting the 
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Akt-elicited promotion of cell survival and thus prevents cell tumorigenesis (Cantley 
and Neel, 1999; Kim and Mak, 2006). CK2 phosphorylates PTEN at C-terminal domain 
to make it inactive. PTEN inactivation promotes Akt pathway thus causing oncogenesis 
(Vazquez et al, 2001). In summary, CK2 kinase plays a pivotal role in the induction of 
Akt pathway in which overexpression or high activity level of this kinase proves to be 
crucial in tumorigenesis (Figure 4). Indeed, in human cancer elevate Akt and lower PTEN 
activities compared to normal healthy cells were demonstrated (He et al, 2007). 
Promyelocytic leukemia protein (PML) is another important tumor suppressor that is 
involved in pathways, like cellular senescence, growth suppression and apoptosis 
(Lallemand-Breitenbach and The, 2006). PML regulates the Akt pathway by interacting 
with two phosphatases, PP2A and the PH domain and leucine rich repeat protein 
phosphatases 2 (PHLPP2), which dephosphorylate Akt at Thr308 activation site (Trotman 
et al, 2006). CK2 kinase affects the function of PML tumor suppressor protein by 
phosphorylating it at Ser517. This phosphorylation leads PML to its degradation by 
proteasome pathway, resulting in avoiding of apoptosis (Scaglioni et al, 2006). In tumors 
where CK2 kinase is hyperactivated, the PML is degraded, which causes loss of tumor 
suppressor activity contributing to induce the tumorigenesis (Duncan and Litchfield, 
2008).  
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Figure 4: Effect of CK2 on PI3K/AKT pathway (Duncan and Litchfield, 2008) 
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1.3.3 CK2 regulation of Wnt pathway  
  
The Wnt signaling pathway plays a crucial role during embryogenesis and is involved in 
cell proliferation, tissue polarity, cell survival, cell fate determination, motility and 
organogenesis (Miller and Moon, 1996; Komiya and Habas, 2008). Wnt signaling has 
essential role in embryogenesis whereas, in adult tissue the activation of Wnt pathway 
leads to tumorigenesis (Gordon and Nusse, 2006).  CK2 phosphorylates different 
intermediates of Wnt pathway which include disheveled (Dvl) (Song et al, 2000), β-
catenin (Song et al, 2000), adenomatous polyposis coli protein (APC) (Homma et al, 
2002) and T-cell factor/lymphoid enhancer factor (TCF/LEF) (Wang and Jones, 2006). 
In Wnt pathway high activity of β-catenin, a pro-transcription cofactor, causes increase in 
pro-survival signals such as c-Myc, cyclin D1 and c-Jun (Dominguez et al ,2004). CK2 is 
known to phosphorylate β-catenin to protect it from degradation by the proteasome. The 
mechanism consists of the dissociation of β-catenin from its destruction protein complex 
which consists of the scaffolding protein, Axin with its associated kinase: the glycogen 
synthase kinase 3 β (GSK3β), APC and PP2A (Song et al, 2003; He et al, 2004). The 
complex dissociation allows the β-catenin to localize into the nucleus, where it activates 
transcription of pro-survival signals (Seldin et al, 2005). One of the β-catenin 
transcriptional target is the inhibitor of apoptosis (IAP), upregulation of which causes 
inactivation of caspases and block of the programmed cell death (Tapia et al, 2006). The 
survivin protein is a member of inhibitor of apoptosis family and it is normally expressed 
during embryogenesis.   Mature cells do not express survivin while, in pathological 
conditions as in a number of cancers it is expressed through β-catenin/TCF pathway,  
which is the result of enhanced activity of CK2 kinase (Duncan and Litchfield, 2008). 
Moreover, transcription factor c-Myc is known to be involved in different types of cancer 
(Ponzielli, et al, 2005). Hyperactive CK2 phosphorylates C-terminal PEST domain of c-
Myc which protects it from proteosomal degradation.  In addition, Wnt pathway β-
catenin/TCF/LEF activates c-Myc transcription which results in the promotion of the 
expression of cell survival genes, the high cellular proliferation rate and cancer 
progression. (Sasaki et al, 2003). 
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1.3.4 CK2 and apoptosis 
 
A key component of normal cell turnover is programmed cell death, also known as 
apoptosis, and its dysregulation is known to be critical in oncogenesis (McKenzie and 
Kyprianou, 2006). CK2 has anti-apoptotic activity and finally increases cell survival by 
several indirect mechanisms, as already described (Ahmad et al, 2008.) CK2 also affects 
apoptosis directly by effecting the caspases activity on the caspases substrates. The 
consensus or recognition sequence of CK2 kinase and those of the caspases have great 
deal of similarity (Litchfield, 2003). When the downstream substrates of caspases are 
phosphorylated by CK2, at the vicinity of caspase recognition site, they are protected from 
cleavage by these proteases. (Krippner-Heidenreich et al, 2001; Riman et al, 2012). Bid, 
a Bcl-2 family protein, is phosphorylated by CK2 kinase at serine residue which the 
recognition site of caspase-8 preventing its cleavage (Desagher et al, 2001). Moreover, 
CK2 kinase has been shown to phosphorylate the activity-regulated cytoskeleton-
associated protein (ARC) resulting in caspase 8 activity inhibition (Li et al, 2002). The 
effect of CK2 kinase on ARC and Bid are depicted in Figure 5. In response to apoptosis 
stimuli, Max, a transcriptional partner of c-myc oncoprotein, is degraded by caspase 
cleavage, whereas, this cleavage is inhibited when Max is phosphorylated by CK2 
(Krippner-Heidenreich et al, 2001). The other examples, in which CK2 phosphorylates 
caspase substrates to protect them against degradation, include the hematopoietic lineage 
cell-specific protein 1 (HS1) (Ruzzene et al, 2002) and gap junction proteins in the lens 
(Yin et al, 2001). Accordingly, studies in which CK2 kinase has been inhibited by 
knockdown or inhibitors demonstrated that cancer cells repurchase their sensitivity to the 
apoptosis stimuli (Ravi and Bedi, 2002). 
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Figure 5: Effect of CK2 on substrates of caspases in apoptosis (Litchfield, 2003) 
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1.4 Inhibitors of CK2 kinase  
 
Since protein kinases are involved in different cell signaling pathways, and dysregulation 
of protein kinases are implicated in tumorigenesis and oncogenesis, this makes them the 
most important pharmacological target. Different powerful inhibitors of kinases have 
been developed for treatment of cancer, these include as Gleevec, Irressa, and Tarceva 
(Klein et, 2005; Krause and Van Ette, 2005). There are two types of Kinase inhibitors, 
competitive and non-competitive. The competitive inhibitors are small-molecules which 
act as adenine mimics, competing with the ATP to the active sites on the kinase (ATP 
binding site) (Prudent and Cochet, 2009). The major issue with competitive inhibitors are 
that they bind to off targets, binding to active sites of other kinases or bind to non-kinases 
which have similar binding sites causing toxicities; Gleevec is a good example which 
causes cardiotoxicity (Kerkela et al, 2006). The other types of kinase inhibitors are those 
which can inhibit the activity of the kinase via allosteric inhibition. In this case, the 
inhibitor-binding site is on the residues away from the catalytic site, causing the change 
in structure and specificity of the substrate, thus inducing downregulation of the kinase 
activity (Garuti et al, 2010).   
CK2 kinase is one of the kinases which has been shown to be a central component of 
different biological processes and its hyperactivity/deregulation has been shown in 
different cancers which makes it a pharmacological target. CX-4945, developed by 
Cylene Pharmaceuticals Inc., is a ATP competitive inhibitor (Ki = 0.38 nM for CK2α and 
CK2α’ with an IC50 of 1 nM) and it is now in second phase of clinical trials (Siddiqui-
Jain et al, 2010). This compound was synthesized from an existing inhibitor of CK2: IQA, 
by modifying thiopene ring within a pyridine ring to incorporate alkyl chains having 
aniline moieties (Pierre et al, 2011). The inhibitor was tested against 238 kinases, which 
showed no extensive inhibitory effects suggesting its high affinity for CK2 kinase (Pierre 
et al, 2011). The studies conducted on PC3 prostate cancer xenograft mice model and PC3 
prostate carcinoma cells showed that the inhibitor was having anti-tumor, anti-
proliferative activity and initiating apoptosis (Kim et al, 2012). Other in vitro experiments 
with BT-474 breast cancer cells should that CX-4945 caused G2/M cell arrest (Siddiqui-
Jain et al, 2010). Clinic trials are being conducted in combination with gemcitabine and 
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cisplatin for treatment of cholangiocarcinoma (ClinicalTrials.gov Identifier 
NCT02128282). The FDA has given CX-4945 Orphan Drug Designation for the treatment 
of cholangiocarcinoma. 
1.5 Mass spectrometry-based proteomics  
 
Proteins act as building blocks of the cell and play a direct role in molecular signaling, 
physical interactions and enzymatic catalysis. The proteins study is most important 
because they are closely related to cell phenotype.  At a global scale, the study of proteins 
is known as proteomics (Yarmush and Jayaraman, 2002). The most comprehensive and 
versatile tool in large-scale proteomics is the use of mass spectrometry (MS) for protein 
characterization (Yates et al, 2009). Mass spectrometry-based proteomics involves 
analysis of protein sources from complex protein samples obtained from cell, tissues of 
body fluids (Aebersold and Mann, 2016). The bottom down approach or shotgun approach 
is used often in proteomics which involves proteolytic digestion of the protein mixture 
and the peptides generated are separated using micro or nano-scale high performance 
liquid chromatography. The peptides injected are eluted by increasing gradient of organic 
solvents. The eluted peptides are ionized using electrospray ionization (Fenn et al, 1989) 
at the entry point of mass spectrometer where they are measured by mass-to-charge ratio 
(m/z) or by tandem mass spectrometric (MS/MS) analysis. In tandem mass spectrometry, 
the mass analyzer selects the precursor ions by performing survey scans (MS1). In the 
second stage, these selected ions are detected in the second mass analyzer (MS2) by 
fragmentation of ions by collision-induced dissociation (CID). This fragmentation 
generates b ions from amino terminus and y ions from carboxyl terminus and calculation 
of difference in mass observed between these fragment ions results in the identification 
of amino acid and of peptide sequence (Steen and Mann, 2004).  
PTM’s play a key role in cell signaling pathways by influencing the properties of 
proteins such as interaction, turnover and localization (Larance and Lamond, 2015). The 
most common PTM’s include phosphorylation (Ser, Thr and Tyr residues), 
ubiquitylation (Lys residue) and acetylation. These modifications provide crucial 
insights into the regulation of protein properties during cell signaling pathways (Olsen 
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et al, 2010). The identification and quantification of PTM’s has been evolved with the 
use of mass spectrometry. The advanced separation techniques, better ionization 
techniques, sensitive analyzers and improved fragmentation methods in tandem mass 
spectrometry have made the mass spectrometry an ideal approach to study PTM’s 
(Silva et al, 2013). These advances allow to identify PTM sites in single experiments. 
Different enrichment strategies could be adopted to capture specifically modified 
peptides to study the global effect of that modification within the proteome. These 
capture strategies include, antibody based enrichment of phospho Ser, Thr, Tyr residues 
(Doll and Burlingame, 2014), Ionic interaction based enrichment, which includes 
immobilized metal affinity chromatography (IMAC) and titanium dioxide (TiO2) to 
capture phosphopeptides (Silva et al, 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 
 
1.6 Aim and proceeding of the project  
The findings in the literature suggest that the majority of substrates of CK2 kinase have 
not been studied and therefore the CK2 dependent cellular signaling events are not fully 
characterized yet. Since CK2 has constitutive catalytic activity, the large scale global 
cellular validation of bona fide substrates is a highly challenging task. In order to 
overcome this limitation, Kevin Shokat and his colleagues developed chemical genetic 
approach in which a gatekeeper residue (bulky residue) is mutated to a smaller residue in 
ATP binding pocket to expand the binding site so that different analogues of ATP can be 
utilized by the analogue sensitive kinases. In this study, the CK2α and CK2α’ gatekeeper 
residues were identified by sequence and structural alignment to other kinases to 
identifying the bulky residue in order to create the analogue sensitive CK2 kinase (as). 
The residues of F113 in CK2α and F114 in CK2α’ were mutated to glycine (a smaller 
amino acid) to open up the space in the ATP binding pocket. We tested different 
commercially available ATP-analogues in vitro by testing the activity of these analogues 
with the recombinant wt and as CK2α and CK2α’. The results showed N6-(2-phenylethyl) 
ATPγS (2peATPγS) can be utilized more efficiently by the as-CK2α and as-CK2α’ 
compared to the wild type.  
Stable cell lines expressing as-CK2α and α’ were developed and characterized. Since the 
ATP-analogue used is not cell permeable, the cells were treated first with digitonin (mild 
detergent) to make the ATP-analogue available, in which cell were added with ATP-
analogue for thiophosphorylation reaction to take place. Thiophosphorylated serine, 
threonine or tyrosine residues were alkylated by PNBM so that the as-CK2 dependent 
phosphorylation could be detected with anti-thiophosphate ester antibody by western to 
compare utilization of the ATP-analogue by wt and as-CK2 kinases. The mass 
spectrometric proteomic approach was used further to ID the thiophosphorylated protein 
in the lysates. The proteins were digested by trypsin and thiophosphorylated peptides were 
captured using Iodoaceytl beads. The captured peptides were run on mass spectrometer 
and were analyzed using Peaks8, the thiophosphorylated protein found only in as-CK2 
were considered to be the substrates of CK2 kinase. The rationale was to optimize a 
workflow which would help in future to develop a strategy to validate the bona fide 
substrates of CK2. 
21 
 
Chapter TWO 
2.1 Material and Methods 
 
2.1.1 Sequence alignment and modelling  
 
Sequence alignments were performed using NCBI COBALT to compare the protein 
sequence of human CK2α (NP_001886) and CK2α’ (NP_001887) with Cdk1 
(NP_001777), Cdk4 (NP_000066), Cdk6 (NP_001250), Cdk7 (NP_001790), and c-Src 
(NP_005408). After Identifying the gatekeeper residue, modelling was done by using 
Pymol. (The alignment experiments were conducted by Michael Gabriel at Litchfield lab) 
 
2.1.2 Site-directed mutagenesis and cloning  
 
Site-directed mutagenesis (Stratagene) was used to substitute CK2αF113 and CK2α’F114 
to a glycine residue with the following primers, respectively: 
5'-TGTTGTTTACGTGTTCACCAACCAAGGCGGGGGTTCGTG-3'    
5'-CACGAACCCCCGCCTTGGTTGGTGAACACGTAAACAACA-3' and  
5'-CTGTATTATTGATATATTCACCTACCAAAGCTGGTGTCTTTGACACGGGG-
3'  
5'-CCCCGTGTCAAAGACACCAGCTTTGGTAGGTGAATATATCAATAATACAG-
3’ 
The vector pGEX having cDNA insert coding for CK2α and CK2α’ with GST tag at their 
N-terminal were used as template for site-directed mutagenesis. The mutagenesis was 
performed using high fidelity Pfu polymerase with the following parameters on Biorad 
thermocycler. 
1. Initial denaturation at 98 °C for 2 min 
2. Denaturation at 98 °C for 40 seconds 
3. Annealing at 58 °C for 30 seconds 
4. Extension at 72 °C for 3.5 min 
5. Final extension at 72 °C for 5 min  
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In total 20 cycles were run from step 2 to 4. After the mutation and amplification, the 
reaction was treated with Dpn I enzyme for 2 hours, the enzyme was inactivated by 
heating at 80 °C. The plasmid DNA was then added into 100 µl of DH5α chemical 
competent cells in the Eppendorf tube. The mixture was mixed gently and was kept on 
ice for cold shock for 25 min. Then, the mixture was placed into a water bath at 42 °C for 
1 min and on ice for 3 min. The mixture was then added with 500 µl of LB media and 
kept at 37 °C in the incubator with agitation for 45 min. Finally, the culture was seeded 
on LB agar plates with ampicillin (100 µg/ml) and the plates were incubated at 37 °C 
overnight. The colonies were picked in, placed in LB media with ampicillin (100 µg/ml) 
and placed at 37 °C with agitation overnight. Next day the Miniprep kit (GeneJetTM) was 
used to isolate the plasmid DNA from the cultures. The Plasmid DNA was sent for 
sequencing to confirm the site-directed mutagenesis.  
 
2.1.3 Protein purifications 
 
The pGEX-wt-CK2α or pGEX-as-CK2α and pGEX-wtCK2α’ or pGEX-as-CK2α’ having 
GST tag on the N-terminal were transformed in BL21 E. coli cells using the method as 
previously mentioned. The colonies were picked and grown in 15 ml 2XYT media (16g 
tryptone, 10g yeast extract, 5g NaCl, 1L ddH20, pH7.0) for each construct as pre-cultures. 
The pre-cultures were grown in 1 liter 2XYT media containing ampicillin (100 μg/ml) at 
37 °C in the shaker incubator. The cells were induced with 0.5mM IPTG at OD600 0.8. 
After induction, the cultures were grown overnight at 16 °C in a shaker incubator. Next 
day, the culture was centrifuged at 4000 RPM and the cells were re-suspended in PBS to 
remove residual media, centrifuged again and supernatant was discarded. The resulting 
cell pellet was re-suspended in resuspension buffer (PBS with 30 mg/ml aprotinin, 20 
mg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride). The cells were passed 
through the homogenizer for cell lysis in the presence of 1% of Triton X-100 to ensure 
the complete lysis of the cells. The cells were tumbled for 15 min. The lysate was 
centrifuged at 10,000 RPM for 20 min at 4 °C. The supernatant was added with 2ml slurry 
of 1:1 Glutatione-agarose: PBS beads. The beads with supernatant were tumbled for 1 
hour at 4 °C. The beads along with the supernatant were added to the gravity columns in 
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which the supernatant was passed through the column and collected. The beads were 
washed 3 times with PBS. After the washes, the beads were added with 1 ml of elution 
buffer 1 (10 mM reduced glutathione, 50 mM Tris–Cl (pH 8.0), 1 mM DTT) and 
incubated for 5 min at 4 °C. After the incubation, the flow, was collected. The elution was 
done 4 times using elution buffer 1. The elution was also done two times using elution 
buffer 2 (30 mM reduced glutathione, 50 mM Tris (pH 8.0), 1 mM DTT). The eluted 
fractions were run on SDS-PAGE gels for confirmations of the presence of proteins in the 
eluted fractions. The fractions 2 to 6 showing presence of the GST-CK2 were pooled 
together, concentrated and the buffer was changed with the Storage buffer (15 mM Mops 
(pH 7.0),0.75 mM DTT, 300 mM (NH4)2SO4, 25% glycerol).  
 
2.1.4 In vitro kinase assay 
 
Recombinant wt-CK2α, as-CK2α and wt-CK2α’, as-CK2α’ kinases were diluted to 50 
ng/μl in CK2 dilution buffer (5 mΜ MOPS pH 7.0, 200 mM NaCl, 1 mg/ml BSA) 
immediately before use in kinase assays. 500 ng of recombinant His-elongation factor 1-
delta (EEF1D), as a substrate, was phosphorylated by CK2 (100 ng) in CK2 kinase assay 
buffer (final concentration of 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM MgCl2, 1 
mM DTT) supplemented with 100 μM ATPγS (Sigma) or N6-modified ATP analogs: N6-
2phenylethyl-adenosine-5’-O-3tthiotriphosphate (2peATγP), N6-Furfuryladenosine-5'-
O-3-thiotriphosphate (6-Fu-ATP-γ-S) and N6- Benzyladenosine-5'-O-3-thiotriphosphate 
(6-Bn-ATP-γ-S) (Biolog).  
Assays were performed at 30°C for 30 min with slight mixing. After 30 min, all the 
reactions were stopped by adding EDTA at final concentration of 50mM. The samples, 
after the thiophosphorylation reactions using 100 μM ATPγS or N6-modified ATPγS, 
were alkylated by treatment with 2.5 mM p-nitrobenzylmesylate (PNBM, Epitomics) for 
2 hours at room temperature. The reactions were stopped by adding 2X Laemmli buffer 
and the samples were boiled for 5 min. The samples were run on 10% SDS-PAGE gels, 
blotted and the membrane was hybridized with thiophosphate ester antibody (Abcam). 
. 
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2.1.5 Competition assays 
 
Competition assays were done using 100 μM 2peATPγS, ATP or GTP in different 
combinations. After the kinase reactions were done, as described in the previous section, 
and the alkylation obtained by incubation with 2.5 mM PNBM for 2 hours, the samples 
were analyzed on Western blots using thiophosphoester antibody to detect 
thiophosphorilated proteins and phospho-S162 EEF1D antibody to detect phosphorilated 
subtrates. 
 
2.1.6 Cell Culturing  
 
U2OS (human bone osteosarcoma cell line) cells were grown in 10 cm or 6 well dishes in 
Dulbecco's Modified Eagle Medium (DMEM) (Gibco-Invitrogen) medium containing 
10% FBS (Invitrogen) and antibiotics (penicillin, 100 units/ml and streptomycin, 0.1 
mg/ml). The cells were grown at 37 °C with 5 % CO2. The cells were allowed to grow up 
to 70 to 80% confluency before proceeding to experiments.  
2.1.7 Optimizing the Digitonin concentration 
 
The analogues of ATP are not cell permeable, so the optimum amount of digitonin to be 
used for the thiophosphorylation experiments were determined by titrating with different 
concentration of digitonin. U2OS cells were grown in 6 cm plates, as described above, to 
80 % confluency. The media was aspirated and cells were washed 3 times with PBS and 
treated with different concentrations of digitonin (Millipore) for 25-30 min. Propidium 
iodide (PI) (Thermo), a nucleic acid stain, was used to observe the permeabilization of the 
cells. After the treatment with digitonin, cells were washed with PBS and then washed 
again with 2XSSC buffer (0.3M NaCl, Sodium Citrate pH7) to remove non-adherent cells. 
The cells were added with SSC buffer having 0.5 mM of PI for around 2 min. The cells 
were washed with 3XSSC buffer. The adherent cells in the 6 well plates were observed 
under Nikon Microscope using TRITC filter.  
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2.1.8 Testing Thiophosphorylation and as-CK2 expression in cells 
 
U2OS cells were grown in 10 cm plates to 80 % confluency. 20 μg of pRC/CMV-as-
CK2α-HA and α’-HA and pRC/CMV wt-CK2α-HA and α’-HA were transiently 
transfected into the cells by using calcium phosphate method (Sambrook et al, 1989). 20 
μg of each pRC/CMV construct was brought a volume of 45 µl with distilled water.  After 
the suspension of each plasmid 5 µl of 3M NaOAc (sodium acetate) and 150 µl of ice cold 
ethanol were added. The suspensions were incubated on ice for 10 min and the plasmid-
DNAs were precipitated by centrifugation at 13000 RPM. The supernatants were 
aspirated and the pellets were allowed to dry in the flow hood. The pellets of each 
plasmids were re-suspended in 450 µl of 0.1x TE. After complete re-suspension 500 µl of 
2X HBS (pH 7.05) were mixed and all suspensions were kept at room temperature for 5 
min. 50 µl of 2.5 M CaCl2 were placed on the side of each tube and tubes were quickly 
vortexed for 15 sec to avoid precipitation formation. 1 ml of the total solution (450 µl 
TE+ 500 µl HBS + 50 µl CaCl2) was added to the 10 cm plates and the medium was gently 
mixed by swirling and all dishes were kept in the incubator for 12 hours. After 12 hours, 
the media were aspirated, the cells were washed 3 times with PBS and supplemented with 
fresh media. Separately, in a 10cm plate, U2OS cells were also transfected by 5 µg of 
eGFP C2 (Clontech) construct using the above-mentioned protocol to check the efficiency 
of the transfection by this method. The cells in the plates were observed under Evos Fl 
Auto (Life technologies) microscope using GFP filter. 
 
After 24 hours, the transfected cells were 3 times washed with PBS and added with 
thiophosphorylation buffer (final concentration: 20 mM HEPES pH 7.5, 5 mM NaOAc, 
100 mM KOAc, 2mM MgOAc2, 1 mM EGTA, 10 mM MgCl2, 0.5 mM DTT, 5mM 
creatine phosphate (Calbiochem), 57 μg/ml creatine kinase (Calbiochem), 5 mM GTP 
(Sigma), 0.1 mM ATP (Sigma), Pepstatin A 2 µg/mL, Aprotinin 10 μg/mL, Leupeptin 1 
mM, PMSF 1 mM, NaF 1 mM Na2VO4 1mM). The buffer was also added with 0.1 mM 
2peATPγS and 30 μg/ml of digitonin to permeabilize the cells. After, the plates were 
placed on the rocker for 40 min at room temperature. The thiophosphorylation buffer was 
aspirated and cells were lysed using Tris lysis buffer (50 mM Tris pH 7.5, 150 mM Nacl, 
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50mM EDTA, 1% NP-40, 0.1 Deoxycholic Acid, Pepstatin A 2 µg/ml, Aprotinin 10 
μg/ml, Leupeptin 1 mM, PMSF 1 mM, NaF 1 mM, Na2VO4 1mM). The samples were 
centrifugated at 15000 rpm for 30 min at 4°C. The samples were moved to a new tube and 
added with 2.5 mM PNBM for 2 hours for alkylation. The reaction was stopped by adding 
2X Laemmli buffer, the samples were run for Immunoblotting and the membranes were 
hybridized with thiophosphate ester antibody, to detect thiophosphorylated proteins, and 
anti-HA 3F10 (Roche) antibody, to detect CK2 constructs expression.  
 
2.2.9 Inducible stable cell lines development 
 
The human osteosarcoma U2OS cell line containing a gene integration site regulated by 
a Tetracycline responsive element (FT-U2OS) were provided by Dr. Karmella Haynes at 
Arizona State University (Haynes and Silver, 2011). Stable cell lines expressing wild type 
CK2α and α’ and analogue sensitive CK2α with c-term HA affinity tag (wt-CK2α, as-
CK2α and as-CK2α’) were generated according to the manual of Flp-In T-REx, 
ThermoFisher Scientific (www.thermofisher.com). wt-CK2α’ stable cell lines were 
already established in Litchfield lab.  FT-U2OS cells were cultured in DMEM (Wisent) 
supplemented with 10% FBS (Thermo Fisher Scientific) and antibiotics (0.1 mg/ml 
streptomycin and 100 units/ml penicillin, Gibco). The cell lines were transfected with of 
plasmid DNA of wt-CK2α-HA, as-CK2α-HA or as-CK2α’-HA insert cloned into 
pcDNATM5/FRT/TO vector and pOG44 (expression of recombinase) in the ratio 1:9 
(both from ThermoFisher Scientific). After the transfection, cells were grown in selective 
media containing 150 g/ml hygromycin B (Wisent) and 15 g/ml blasticidine (Wisent).  
The surviving cells were grown until confluency in the selectable media. The cells were 
induced by different concentrations of tetracycline (from 0.2 to 1 g/ml) or at the highest 
concentration (1 g/ml) at different time points (from 15 min to 24 hours). The cells were 
harvested using TLB lysis buffer (50 mM Tris pH 7.5, 150 mM Nacl, 1% NP-40, 0.1% 
deoxycholic acid) with additional protease and phosphatase inhibitors (1 mM PMSF, 7 
g/ml PepstatinA, 20 g/ml Leupeptin, 2.9 g/ml Aprotinin, 1 M Okadaic acid, 1 M 
Microcystin, 5 mM NaF, 1 mM sodium orthovanadate). Cell lysates were centrifuged at 
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2000 x g at 4C for 15 minutes and were immunoblotted with the HA-3F10 antibody to 
check the expression of the different exogenous proteins. 
 
2.1.10 Immunoprecipitation 
 
Stable U2OS Flp-in wt-CK2α, as-CK2α and as-CK2α’ cell lines were grown in DMEM 
media with 150 g/ml hygromycin B and 15 g/ml blasticidine, as described before. After 
reaching confluency, the cells were induced with 1 μg/ml of tetracycline for 24 hours. The 
cells were lysed in TLB buffer (with protease and phosphatase inhibitors) and protein 
concentration was determined by BCA assay (Thermo Fisher Scientific). Total of 300 µg 
of lysate was used for immunoprecipitation. The lysates were precleared by adding 30 µl 
of PGS bead slurry. The slurry was tumbled on a rotator for 30 min at 4 C. The lysate 
and beads were centrifuged at 13000 rpm for 2 min and the supernatant was transferred 
to a new tube. The lysates were added each with 0.5 µl of HA12CA5 (Roche) antibody 
and tumbled on rotator for 1 hour at 4 C. After one hour, lysates were added with 30 µl 
of PGS bead slurry and additionally tumbled for another hour. The suspensions were than 
centrifuged at 13000 rpm for 5 min, the supernatants were aspirated and beads were 
washed 3 times with TLB buffer. After washing, Laemmli buffer was added to the beads 
of each sample and the suspensions were heated at 95 C for 3 min. The beads were 
centrifuged and the supernatants were analyzed on the blot.  
2.1.11 Immunofluorescence 
 
Stable U2OS Flp-in wt-CK2α, as-CK2α and as-CK2α’ cell lines were grown on coverslips 
in 6 cm plates with DMEM media in the presence of selective markers, as previously 
described. After reaching confluency, cells were washed 3 times with cold PBS. The cells 
were fixed on the cover slips using 10% formalin for 15 min. After fixing, the cells were 
washed 3 times with PBS. The cells were then permeabilized using 0.1% Triton-X 100. 
Permeabilization was followed by 3 washes of PBS and blocking with 3% BSA in PBS 
for 1 hour. The cells were incubated with 50 µl per well of HA-Alexa Fluor® 488 
conjugated antibody (1:400 in 3% BSA PBST, Invitrogen) for 1 hour at room temperature 
for hybridization. After, the cells were washed with PBS and added with 50 µl of 1 µg/ml 
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of Hoescht 33258 nuclei stain (Thermo Fisher Scientific). Glass cover slips were washed 
3 times with cold PBS and mounted on glass slide using mounting media. Next day the 
images were acquired on Nikon Eclipse microscope at 20X magnification using FITC 
filter for HA-conjugated antibody and DAPI for Hoescht staining of nuclei. 
 
2.1.12 SILAC (Stable Isotopic Labeling of Amino Acids in Cell Culture) labeling and 
incorporation 
 
The stable cell lines were grown in the growth medium (DMEM, Wisent) supplemented 
with stable isotope labels. The media were supplemented with unlabeled L-lysine and L-
arginine (Silantes GmbH) at concentrations of 83.1 mg/l and 60 mg/l for ”Light media” 
(Lys0; Arg0), isotopically labeled L-lysine-2HCl 4,4,5,5-D4  and L-arginine-HCl13C6 at 
concentrations of 86.2 mg/l and 61.14 mg/l for “Medium” media (Lys4; Arg6), and 
isotopically labeled L-lysine-2HCl13C615N2 and L-arginine-HCl13C615N4 at 
concentrations of 52.4 mg/L and 87.7 mg/L for “Heavy” media (Lys8; Arg10). Unlabeled 
L-proline (Cambridge Isotope Laboratories Inc) was supplemented at 400 mg/l in all the 
SILAC label media. The SILAC were also supplemented with 10% dialyzed FBS 
(Corning) and antibiotics (0.1 mg/ml streptomycin and 100 units/ml penicillin, 150 g/ml 
hygromycin B and 15 g/ml blasticidine). 
FT-U2OS stable cells were adapted in their respective media as-CK2α and α’ (heavy 
media) (Lys8; Arg10), wt-CK2α and α’ (medium media) (Lys4; Arg6) and U2OS parental 
cell lines in light media (Lys0; Arg0) over a period of 7 passages. The cells were than 
lysed, as mentioned before, and precipitated using methanol/chloroform method. The 
proteins were digested using Trypsin (Pierce) (1:100) (refer to section 2.1.14 for 
precipitation and digestion method). The peptides were run on Orbitrap Elite mass 
spectrometer.  The raw data obtained from the run was analyzed by using MaxQuant 
v1.5.3.8 (Cox and Mann, 2008) and searched against Swissprot-Uniiprot database (homo 
sapiens taxon, accessed on December 26, 2015). The search on MaxQuant was set to 
multiplicity of 2, with heavy labels selected as Arg10 and Lys8. Mass tolerances were set 
to 4.5 ppm for the parent ion mass (MS) and 0.5 Da for the fragment ion mass (MS/MS). 
FDR was set to 1% and trypsin was selected with maximum of 3 missed cleavages. The 
variable modifications selected were, methionine oxidation (+15.9949), protein N-
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terminus acetylation (+42.0105), asparagine and glutamine deamidation (+0.9840Da). 
Cysteine carbamidomethylation (+ 57.0215) was set as a fixed modification and Re-
Quantify option was turned on. The data acquired from MaxQuant was then loaded into 
Perseus version 1.5.2.6 (Tyanova et al, 2016). The “evidence.txt” file was used to extract 
information about peptides that were quantified in MS1 and identified in MS2. The 
heavy/light (H/L) ratios were calculated using heavy and light intensity values from MS1 
quantitation. The calculation used to calculate incorporation was: H/L ratios larger than 1 
were calculated with (100 – (1/ratio)x100), and ratios less than 1 were calculated with 
(ratio x 100). The median of all incorporation values for each individual SILAC pair was 
calculated and represents the incorporation efficiency for the labeled amino acids. 
 
2.1.13 Thiophosphrylation reaction  
 
 FT-U2OS stable cell lines expressing as-CK2α and α’ were grown in heavy media (Lys8; 
Arg10), wt-CK2α and α’ in medium media (Lys4; Arg6), and U2OS parental cell lines in 
light media (Lys0; Arg0) SILAC media. These stable cell lines were grown in labelling 
media for seven cell divisions. The cells were tested for label incorporation of >95 
percent.  After checking the incorporation, stable cell lines were grown in 15 cm dishes 
to reach 80% confluence in their respective labelled media and were induced for 24 hours 
with 1 μg/ml tetracycline. After 24 hours, cells were harvested in NP-40 Lysis Buffer (50 
mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 1 μg/ml Pepstatin A, 2 µg/ml Aprotinin, 
10 μg/ml Leupeptin, 1 mM PMSF, 1 mM NaF, 1 mM Na2VO4), and lysed by sonicating 
for 3 x 15 sec on ice. Kinase assays were performed by supplementing 1 mg of lysate with 
CK2 kinase assay buffer (final concentration: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 
mM MgCl2 with 0.3 mM GTP,100 μM ATP and 100 μM 2peATPγS) and incubating for 
30 min at 30 °C with gentle shaking. The reaction was stopped with addition of 50mM 
EDTA (final concentration).  10 µg of lysate from each reaction was taken and alkylated 
in solution by the addition of PNBM (2.5 mM) for 2 hours, then they were analyzed by 
western blot analysis using thioester antibody. The thiophosphorylation reaction for each 
label was done in nine biological replicates.  
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2.1.14 Thiophospho peptide capture for mass spectrometric analysis 
 
After the kinase reaction, the lysates from all 3 labels were mixed at 1:1:1 ratio and the 
proteins were precipitated using a methanol/chloroform method (Rappsilber et at, 2007). 
Briefly, the lysate volume was brought up to 200 l with mass spec grade water (Pierce). 
Each sample was also added with 800 l of methanol and 200 l of chloroform and it was 
vortexed briefly. Then, it was added with 600 l of water and vortexed again. Each sample 
was centrifuged for 10 min at 130000 rpm. The supernatant was aspirated and additional 
wash was done using 800 l of methanol. After washing, it was centrifuged for 10 min at 
130000 rpm and the supernatant was aspirated. The pellet obtained was re-suspended in 
50mM Tris pH 8 and 10 mM TCEP. Proteins were digested with the addition of 
Trypsin/LysC (Promega) at 1:100 (w/w) ratio for 4 hours at 37 °C. Additional Trypsin 
(Pierce) (1:100) was added and the sample was incubated overnight at 37 °C.  
UltralinkTM Iodoacetyl beads were washed with 50mM Tris pH 8 for 3 times. 200 µl of 
beads were added to each mg of protein used. The tubes with peptides and beads were 
rotated in dark overnight. Next day, the beads were washed with 1 ml of, in the following 
sequence:  H2O, 5M NaCl, 50% ACN, and 5% formic acid. Following the washes, beads 
were treated with 500µl of Oxone solution (1mg/ml) for 30 min to elute the 
thiophosphorylated peptides from the beads. The eluted peptides were concentrated to 
~200μl using a SpeedVac Concentrator and desalted using C18 Stage Tips (Empore) 
according to a protocol of Rappsilber et at, 2007. The concentrated peptides were 
quantified using NanoDropTM (Thermo Fisher Scientific). 0.8 μg of peptides were loaded 
on the mass spectrometer. 
2.1.15 Mass Spectrometry  
 
Protein digests were analyzed using an Orbitrap Elite Hybrid Ion Trap-Orbitrap mass 
spectrometer coupled with an M-class nanoAquity UHPLC system (Waters) via a 
NanoFlex (Thermo Electron Corp., Waltham, MA) nanospray ionization. The Buffers 
used were Buffer A (Water/0.1% formic acid (FA)) and Buffer B (Acetonitrile 
(ACN)/0.1% FA). Peptides, re-suspended in 0.1% FA, were trapped for 4 min at a flow 
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rate of 10 μl/min at 99% of A/1% B using an ACQUITY UPLC M-Class Symmetry C18 
Trap Column (5 μm, 180 μm x 20 mm). After trapping, peptides were separated on an 
ACQUITY UPLC M-Class Peptide BEH C18 Column, 130 Å, 1.7 μm, 75 μm × 250 mm 
operating at a flow rate of 300 nl/min at 35°C using a 130 min non-linear gradient: 5% B 
over 1 min, 7.5% B over 59 min, 25% B over 14 min, 32.5% B over 6 min, 60% B over 
5 min, 98% B over 10 min, 2% B over 10 min, 98% B over 10 min, and 5% B over 15 
min. 
The mass spectrometer was controlled by Xcalibur software (Thermo, v. 2.7.0) and 
operated in the data-dependent mode using an FT/IT/CID Top 20 scheme.  The MS scan 
recorded the mass-to-charge ratios (m/z) of ions over the range of 400–1450 in FT 
(resolution of 120000 at m/z 400), positive ion, profile, full MS mode using a lock mass 
(445.120025 m/z). The 20 most abundant multiply charged ions were automatically 
selected for subsequent collisional induced dissociation in ion trap mode (IT/CID) with 
an isolation width of 2.00 Da, rapid scan rate, centroid mode, with charge state filtering 
allowing only ions of +2, +3, and +4 charged states.  Normalized Collision energy was 
35, and precursor ions were then excluded from further CID for 30 s. 
2.1.16 Peaks analysis  
The raw data were analyzed using PEAKS Studio 8.0 (Bioinformatics Solutions Inc., 
Waterloo, ON, Canada). Precursor mass error tolerance was set to 4.5 ppm and fragment 
ion mass error tolerance was set to 0.5 Da. Trypsin was selected as an enzyme and up to 
three missed cleavages and one non-specific cleavage were allowed. Variable 
modifications were selected as follows: phosphorylation of Serine and Threonine, 
oxidation of Methionine, deamidation od Asparagine and Glutamine, acetylation of 
protein N terminus, (4,4,5,5)-deuterated Lysine and 13C(6) Arginine (Medium SILAC 
label), and 13C(6)15N(2) Lysine and 13C(6)15N(4) Arginine (Heavy SILAC label). The 
maximum number of variable modifications was set to 4. The false discovery rate was set 
to 1%. Following de novo sequencing, data were searched against the UniProt sequence 
database (homo sapiens taxonomy, accessed on February19, 2017). The unique 
phosphopeptides found only in a Heavy label based on the identification were considered 
as CK2 substrates. The unique phosphopeptides were identified and filtered using a 
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peptide confidence level of >=99% (-10logP value of >=20) and a phosphorylation site 
localization confidence of >=99% (AScore value of >=20) as per PEAKS scoring. The 
list of phosphopeptide/proteins were analyzed through KinomeXplorer (Horn et al, 2014) 
and Phosphositeplus (Hornbeck et al, 2012) for finding putative substrates of CK2. 
2.1.17Gel electrophoresis and immunoblotting 
 
Protein concentration was determined by BCA using BSA standards and absorbance 
measured on a Victor3 V 1420 multilabel counter (Perkin Elmer). Proteins were separated 
by 12% SDS-PAGE, and transferred to PVDF membrane (Millipore). The electrophoresis 
was done in running buffer (Tris 25mM PH 8.3, Glycine 200 mM and SDS 0.1%) at 120 
V initially to allow the proteins to pass through stalking gel, then the voltage was 
increased to 160 V when protein reached the running gel. The transfer was done on ice in 
transfer buffer (Tris 25mM PH 8.3, Glycine 200 mM, methanol 10 %) at 400 mA for 1 
hour. Membranes were blocked in 5% BSA/TBST for 1 hour at room temperature with 
rocking. Thiophosphorylation was analyzed by immunoblotting with anti-thiophosphate 
ester antibody (1:2,000 in 5% milk/TBST, Epitomics) and phosphorylation was analyzed 
by anti-phospho-S162 EEF1D antibody (1:20,000 in 3% BSA/TBST).  Expression of 
transiently transfected HA-tagged proteins was observed with anti-HA-3F10 antibody 
(1:500 in 3% BSA/PBST, Roche). Membranes were incubated with primary antibodies at 
4°C overnight with rocking. Membranes were incubated with secondary antibody 
(1:10,000 GAR800 or 1:10,000 GAM680 in 5% BSA/TBST, Mandel) for 45 min at room 
temperature with rocking. The immunoblots were scanned and quantified using the LiCor 
Odyssey System (LI-COR Biosciences). 
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2.2 Results and Discussion 
 
2.2.1 Identification of the gatekeeper residue in CK2 
 
The chemical genetic approach pioneered by Shokat and colleagues exploits the highly 
conserved structure of the nucleotide-binding pocket among protein kinases. Within this 
site, there is a strictly conserved bulky residue, called the “gatekeeper” residue. The 
mutation of this residue in a number of protein kinases generates analog-sensitive kinases 
(as-kinases) with altered nucleotide requirements as the gatekeeper residue acts as a 
natural steric barrier to bulky ATP analogs. 
The mammalian CK2 family is composed of two catalytic subunits, CK2α and CK2α’, 
and two regulatory subunits, CK2β. To adapt the gatekeeper strategy to CK2 and engineer 
an as-CK2 kinase, the protein sequences of both CK2α and CK2α’ were aligned with 
closely related cyclin-dependent kinases (Cdks) Cdk1, Cdk4, Cdk6, and Cdk7 as well as 
c-Src (Figure 1a). The sequence alignment identified a phenylalanine, F113 and F114 in 
CK2α and CK2α’, respectively, that aligns with conserved bulky threonine and 
phenylalanine residues in c-Src and Cdks. To further confirm this phenylalanine as the 
gatekeeper residue in CK2, the available structures of c-Src, Cdk6, and Cdk7 were aligned 
with those of CK2α (Figure 1b). The gatekeeper residues are highlighted and clearly 
demonstrate that these residues are superimposed on one another. In CK2α, F113 is 
located in the back of the nucleotide-binding pocket (Figure 1c). The mutation of this 
residue to a glycine enlarged the pocket as illustrated by an in silico substitution (Figure 
1d).  
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Figure 1. Identification of the gatekeeper residue in CK2. (a) A sequence alignment of the 
catalytic subunits CK2α and CK2α’ with c-Src, Cdk1, Cdk2, Cdk4, Cdk6, and Cdk7 identifies a 
conserved phenylalanine, F113 and F114 in CK2α and CK2α’, respectively (the gatekeeper 
residue is bolded and denoted by *). (b) A structural alignment highlighting the gatekeeper 
residues in CK2α (yellow) with c-Src (red), Cdk6 (blue), and Cdk7 (green). ATP is coloured in cyan. 
An insilico substitution of the gatekeeper residue in CK2α (c) with a glycine in as-CK2α (d), 
illustrates the enlargement of the nucleotide-binding pocket. The gatekeeper residue is coloured 
in magenta. The substitution was introduced using Swiss PDB Viewer and images were created 
in PyMol. PDB: CK2α, 1JWH; c-Src, 3EL7; Cdk6, 4EZ5; Cdk7, IUA2. 
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2.2.2 Purification of GST tagged proteins 
 
pGEX-wt-CK2α or pGEX-as-CK2α and pGEX-wt-CK2α’ or pGEX-as-CK2α’, which 
were GST tagged proteins, were purified using Glutatione-agarose beads. The elution of 
the proteins was done in 4 fractions of 1 ml each with 10mM Glutatione and 2 fractions 
of 1 ml each with 30 mM Glutatione. All the fractions were run on SDS-PAGE gel (Figure 
2A and 2B). The fractions 3 to 6 showed less contaminants, so these fractions were pooled 
together. After pooling, the fractions were dialyzed and concentrated. The concentration 
was determined by using Bradford assay. The concentrated samples were loaded on SDS-
PAGE, to see if some contaminants are present or not (Figure 2C), together with the 
known concentrations of BSA protein for comparison. The as-CK2α and α’ show little 
more contaminants when compared with the wild type ones. This could be due to the 
partial degradation of the as-kinases because the mutation is reported to cause kinase 
unstability and degradation.    
Moreover, single bands were observed on SDS-PAGE profile of as-CK2α’ as well as wt-
CK2α’, while, two bands are observed on SDS-PAGE profile of both as-CK2α and wt-
CK2α. These double bands might be due to the proteolytic cleavage on the C-terminal of 
the α subunit of the kinase which has been reported by Grasselli et al., 2003. It is worth 
mentioning that previous data in the literature have demonstrated that this cleavage does 
not alter the activity of the kinase since a robust activity has been documented even if the 
part of C-terminal domain is cleavaged (Turowec et al, 2010).  
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Figure 2: Purification of recombinant wt and as-CK2α and α’. (A) SDS gel profile of DB1 
(wt-CK2α) and DB6 (wt-CK2α’). The fractions of un-purified and purified GST tag proteins were 
loaded on the gel to visualize their degree of purity. The treatment with different concentrations 
of glutathione shows the elution of specific proteins. The eluted samples were compared to these 
washed just with PBS. The detail of coding for sample is presented in the figure. (B) SDS gel 
profile of as-CK2α and as-CK2α’. The fractions of un-purified and purified GST tag proteins were 
loaded on the gel to visualize their degree of purity. The treatment with different concentrations 
of glutathione shows the elution of specific proteins from the beads. The eluted samples were 
compared to these washed just with PBS. The detail of coding for sample is presented in the figure. 
(C) After dialyzing and concentration, proteins were quantified using BCA assay and loaded onto 
the gel together with well-known concentration of BSA for comparison. 
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2.2.3 In vitro kinase assay using different ATP analogues 
 
Previous work of Grankowski et al. reported that the catalytic subunits of CK2 kinase 
tend to have robust activities without the presence of their regulatory subunits when they 
are expressed in bacterial system.  This indicates that CK2α and α’, in this system, are 
constitutively actives (Grankowski et al, 1991) and do not require any external stimuli for 
activation. This makes it possible to just use the catalytic subunits for the in vitro assays 
also because the GST tag on the N-terminal of the proteins does not alter the activity or 
specificity of each catalytic subunits (Turowec et al, 2010).  
Kinase assays with recombinant wt-CK2α, as-CK2α and α’ kinases were performed using 
EEF1D as a substrate to screen three commercially available N6-modified ATP analogs: 
2peATP-γ-S, Fu-ATP-γ-S and Bn-ATP-γ-S (Figure 3A and 3B). EEF1D was used as it is 
a well-known and documented substrate of CK2 kinase which is readily phosphorylated 
at residue S162 (Gyenis et al, 2011).  The kinase reactions were started with the addition 
of ATP-analogues. After the reaction, the samples were treated with PNBM, an alkylating 
reagent, which adds the alkyl group to form thioester bonds, that could be detected by 
anti-thioester antibody (Allen et al, 2007). In the presence of wt-CK2α and α’, robust 
phosphorylation of the EEF1D was observed with ATPγS while with the ATP analogs, 
wt-CK2 α and α’ also had weak activity with Fu-ATP-γ-S and Bn-ATP-γ-S and with 
2peATP-γ-S analog (Figure 3b). In contrast, as-CK2α and α’, showed marginal activity 
with ATPγS but increased thiophosphorylation efficiency of EEF1D with 2peATP-γ-S. 
Minimal phosphorylation was detected using the other N6-modified ATP analogs. This 
screen identified efficient utilization of 2peATP-γ-S by as-CK2 in contrast to the low 
activity level observed for wt-CK2.  
In principle, the gatekeeper residue in the ATP binding pocket is hydrophobic and is 
known to act as hydrophobic spine which promotes enzymatic activity, indeed the 
mutation of this residue causes opening of the ATP binding pocket and may reduce 
activity or make the kinase completely inactive (Azam et al, 2008). In that case this 
problem could be overcome by introducing another mutation in β-sheet the N-terminal 
lobe of the kinase to branched aliphatic residues e.g. isoleucine or valine, which can 
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increase its activity (Bishop et al, 2000). This is not our case since the in vitro kinase assay 
suggests that the mutation did not affect the kinase activity but only changes the 
selectively for the co-substrate ATP as as-CK2α and α’ are able to use the ATP-analogue 
(2peATP-γ-S) better than ATPγS. 
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Figure 3. Screening catalytic activity of CK2 with N6-substituted ATP analogs reveals utilization of 
2peATP by as-CK2. (A) wt and as-CK2α (B) wt and as-CK2α’. The chemical structure of ATP 
illustrating the addition of bulky chemical groups at the N6-position on the adenine ring as denoted by R. 
The catalytic activity of wt- and as-CK2 was assessed with EEF1D using N6-substituted ATP analogs, 
(2peATγP), (6-Fu-ATP-γ-S) (6-Bn-ATP-γ-S). Phosphorylation was detected by immunoblotting with 
Thiophospho ester antibody after treatment with PNBM. 
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2.2.4 as-CK2 utilizes 2peATP-γ-S more efficiently 
   
In an effort to further investigate the observation that as-CK2 has a higher affinity for 
2peATPγ-S, competition experiments were performed. Phosphorylation of EEF1D 
substrate by wt-CK2α and α’ with ATP and GTP was unaffected by the addition of same 
concentrations of 2peATPγS as no change in the utilization of ATP and GTP was 
observed (Figure 4 A and B). However, the utilization of 2peATPγS was minimal by wt-
CK2 when it was added with ATP or GTP. These results show that ATP and GTP are 
preferred to be used by wt-CK2. In the similar way, for as-CK2, thiophosphorylation with 
2peATPγS was not affected by the addition of ATP or GTP. This result indicates that ATP 
cannot efficiently compete with 2peATP for binding to the active site of as-CK2, further 
reinforcing the observation that as-CK2 preferentially uses 2peATP. 
The goal of the competition assays were to confirm that the utilization of the 2peATPγS 
would be preferred by the analogue mutants in the cellular environment where ATP and 
GTP are present. These results had formed bases to make transition from in vitro assays 
to complexity of in vivo cell line experiments in order to investigate direct substrates of 
CK2 kinase.  
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Figure 4. As-CK2 preferentially uses 2peATP over ATP and GTP. (A) wt and as-CK2α; (B) 
wt and as-CK2α’. Kinase assays were performed to evaluate the preferential use of 2peATPγS, 
ATP and GTP. (A) Recombinant His-EEF1D was phosphorylated by wt-CK2 and as-CK2 using 
2peATPγS, ATP ad GTP in different combinations. Thiophosphorylation was detected by anti-
thiophosphoester antibody and EEF1D S162 phosphorilation by anti-phospho antibody. Total 
CK-2 kinases were detected by anti-CK2α or α’ antibodies. 
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2.2.5 Optimizing Digitonin concentrations 
 
N6-ATP-analogues are not permeable through the cell membrane. In order to make ATP-
analogues to be available for the cell, digitonin was used, which is a mild non-ionic 
detergent able to permeabilizes cellular membranes. Digitonin treatment on unfixed cell 
has been used in the literature (Tissera et al; 2010) where it has been reported that cellular 
components stay intact under the permeabilization condition (Chaudhary et al; 2002). In 
particular, DNA functions, actin structures, PDGFR, and membrane-integrated molecules 
remain responsive even after permeabilization (Chaudhary et al; 2002). It is known that 
digitonin treated cells have been able to successfully reverse permeabilization (Miyamoto 
et al, 2008) suggesting that the cells were not completely damaged when treated with 
digitonin. This shows that permeabilization could be utilized to allow the bulky ATP-
analogue to enter into the cells without affecting its cellular machinery and kinase activity. 
Thus, the permeabilizing property of digitonin was utilized to make 2peATPγS to enter 
the cell and to be used by as-CK2α and α’. Titration of digitonin was done in cells to know 
its optimum concentrations. PI stain, which is a red fluorescent nuclear stain, was used to 
detect if the cells were permeabilizated. The Nikon images observed with PI stain shows 
that the cells were adherent to plates but were not permeabilized at low concentration of 
digitonin. 30g/ml of digitonin seemed optimum concentration at which cells were 
permeable and still adherent to plate (Figure 5A). Digitonin concentration higher than 30 
g/ml killed most of the cells, since the number of cells after treatment was very low in 
comparison to the number of cells initially seeded on the plates (Figure 5B). So, for further 
experiments, 30 g/ml of digitonin was used for cells permeabilization.  
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Figure 5: Setup of different concentrations of digitonin for cell permeabilization 
U2OS cells were treated for 25 min with different concentration (from 20 to 40 g /ml) of 
digitonin to permeabilize cells. The cells were observed at 20x magnification under Evos 
microscope using FITC filter (A). The histogram represents the percentage of permeabilized cells 
at different concentrations of digitonin with respect to the total number of cells initially seeded on 
the plates.  Mean ±  standard error of at least three separate experiments.  (B). 
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2.2.6 as-CK2 expression in cells and its utilization of 2peATPγS for thiophosphorylation 
 
The pRC/CMV as-CK2α-HA-C-terminal, wt-CK2α-HA-C-terminal, as-CK2α’-HA-C-
terminal, as well as as-CK2-HA-α’ N-terminal and wt-CK2-HA-α’ C-terminal, were 
transiently transfected in U20S cells. Transient transfections of constructs in the cells were 
done to check both, the level of expression between the wild type and mutant subunits, 
and the utilization of 2peATPγS by wt-CK2α and the analogue mutants. The additional 
construct of as-CK2 HA-α’ N-terminal was utilized to check whether the tag is 
influencing the expression of the protein or not (the expression of wtCK2α’ with HA tag 
on N-terminal had previously shown in Litchfield lab to be expressed less, data not 
shown). The transfection efficiency was checked by transfecting eGFP construct in the 
cells as well. After 24 hours, approximately, 50 % of the cells were expressing the 
construct (Figure 6) suggesting that the overall transfection efficiency was appropriate 
using this method. Immunoblotting with HA-3F10 antibody was done to check the as-
CK2α and α’ expression. Thiophosphate-ester antibody was used to verify if the as-CK2α 
and α’ were also active in the cells. The blot showed that both pRC/CMV as-CK2α-HA 
and pRC/CMV as-CK2α’-HA were expressed equally when compared with the wt-CK2α-
HA and wt-CK2-HA-α’(Figure 7). The expression of as-CK2-HA-α’N-terminal tag was 
lower when compared to other constructs with HA tag on the C-terminal, as expected 
from previous experiments (data not shown).  
The thiophosphorylation reaction was done on the cells transiently expressing wild type 
or mutant catalytic subunits.  The permeabilization of the cells was done with a buffer 
containing digitonin and a cocktail of 2peATPγS, ATP and GTP. After 30 min of 
incubation to perform the thiophosphorylation reaction, the cells were lysed and treated 
with PMBM. The lysates were blotted and the membrane was hybridized with anti-
thiophosphate ester antibody. The recombinant competition assays, described in the 
previous section, indicated that as-CK2 can utilize 2peATPγS efficiently in the presence 
of ATP and GTP, whereas, wt-CK2 catalytic subunit prefer ATP and GTP instead of 
2peATPγS. These results were confirmed in the in vivo experiments since the blots 
(Figure 5) show that both as-CK2α and α’(C-terminal HA tag) show more intensity of the 
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bands with thiophosphate ester antibody compared to the bands of wt-CK2α and α’. In 
conclusion, in the in vivo system, our results show that: 
a) the expression of analogues sensitive CK2 α and α’ kinases are not affected by the 
mutation in the ATP binding pocket, which may cause degradation of the proteins; b) the 
expressed mutants are active in using 2peATPγS.  
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Figure 6 Transfection efficiency using CaCl2: The eGFP construct was transfected using 
CaCl2 method, after 24 hours the GFP emission was observed at 20x magnification under Evos 
microscope using eGFP filter. The transfection efficiency was observed to be around 50 %. 
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Figure 7 : Transient expression of as-CK2α and α’ and thiophosphorylation. U2OS cells were 
transfected with wt and as-CK2α and α’ with HA tag on C-terminal and additional as-CK2α’ with 
HA tag on N-terminal. The cells were treated with 30 µg/ml digitonin, and cells were added with 
2peATPγS and alkylated. Thiophosphorylation was detected by anti-thiophosphate ester antibody 
and expression of all protein constructs were detected by HA-3F10 antibody in immunoblot 
analysis. The amount of thiophosphorylation was calculated by the densitometric analysis of the 
bands on the blots detected by anti-thiophosphate ester antibody in immunoblot analysis for three 
different experiments. The amount of thiophosphorylation, in each experiment, is normalized due 
to the different level of expression within all protein constructs.  
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2.2.7 Stable cell line characterization 
  
Flp-in system is efficient in generating inducible cell lines and allows polyclonal 
selection. The U2OS Flp-in cells consists of integrated FRT (pFRT/lacZeo vector) site, 
where the integration of gene of interest takes place through pCDNA5 (cDNA construct) 
and pOG44.  The pOG44 construct expresses Flp recombinase so that the integration of 
pCDNA5 construct could take place and produce hygromycin resistance. The stable 
expression is under tetracycline control, regulated by CMV promoter. The U2OS stable 
cell lines expressing as-CK2α and α’ and wt-CK2α were generated using Flp-in Trex 
system. The stable cell line expressing wt-CK2α’ were previously established in 
Litchfield Lab (data not shown). To determine the optimum condition to obtain maximum 
expression of exogenous proteins the experiments were performed at different time points. 
Moreover, after 24 hours of treatment, the expression of the exogenous proteins in all 
three stable cell lines, after inducton with concentration of tetracycline (from 0.2 to 1 
µg/ml), were measured by western blotting (HA3F10 antibody). The expression of wt-
CK2α (Figure 8A), and as-CK2α (Figure 8B) were increased with the doses of 
tetracycline. In fact, both as-CK2α and wt-CK2α showed maximum expression at 1 
µg/ml. The as-CK2α’ (Figure 8C) showed similar expression level at all concentration 
although the expression at the dose of 0.2 µg/ml seems slightly higher. It should be note 
that, at all doses tested, the expression level of as-CK2α’ is lower in comparison to those 
of wt-CK2α and as-CK2α. The expression of the total Ck2 kinase was detected by CK2α 
antibody.Further, time course analysis was performed to determine at which time point 
maximum expression could be attained. Thus, all cell lines were induced with 1 µg/ml of 
tetracycline and harvested at different time points. In all cases the maximum amount of 
expression of exogenous proteins was observed at 24 hours after tetracycline induction. 
(Figure 9A and B). The results, once again, showed that the as-CK2α’ shows less 
expression when compared to the other two cell lines.  
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Figure 8: Flp-In U2OS stable cell lines expression using different concentrations of 
tetracycline: Stable Flp-In U2OS cell lines were induced to express the exogenous proteins with 
different concentrations of tetracycline for 24 hours. Stable cell line expressing wt-CK2α (A), as-
CK2α (B) and as-CK2α’(C) were shown. Expression levels of stable cell line were measured 
using HA3f10, CK2α and GAPDH antibodies without tetracycline or after induction with 
different concentration of tetracycline for 24 hours.  
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Figure 9: Time course analysis: comparison of time course induction by 1 μg/ml of 
tetracycline between wt-CK2α and as-CK2α (A), and between wt-CK2α and as-CK2α’ (B). 
The stable Flp-In U2OS cell lines, induced to express the exogenous proteins with 1 μg/ml 
tetracycline, were harvested at different time points. The blots were hybridized with HA3F10, 
CK2α and GAPDH antibodies.  
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In order to further characterize the stable cell lines, immunoblotting and 
immunofluorescence were done to compare the level of expression of as-CK2α and α’ 
versus those of wt-CK2α and to determine if the expression in the cells is homogeneous. 
The subsequent experiments were performed using 1 µg/ml of tetracycline for 24 hours 
to acquire maximum expression.  
The Immunoprecipitation (IP) experiments were done by using PGS beads (conjugated 
with HA3F10 antibody) to pull down the expressed proteins. The lysates and IP pull down 
fractions from induced and non-induced cells, were analyzed by western blots (Figure 
10). The IP captures showed the same profile as the respective lysates suggesting that the 
IP’s were successful and confirming that the as-CK2α’ expression is less compared to 
other proteins.  
Immunofluorescence assays were done to demonstrated if the expression of exogenous 
proteins in the three cells lines were homogeneous. The expression of wt-CK2α-HA 
(Figure 11A), as-CK2α-HA (Figure 11B) and as-CK2α’-HA (Figure 11C) is evident in 
the microscopic images only after the induction with tetracycline. wt-CK2α-HA and as-
CK2α-HA show similar expression profile, as-CK2α’-HA shows comparatively less 
expression. The not homogenous expression in all the cells could be due to polyclonal 
rather than monoclonal method adopted to grow the stable cell lines.  
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Figure 10: Immunoprecipitation of induced wt-CK2α, as-CK2α and as-CK2α’ stable Flp-In 
U2OS cell lines. All three cell lines were induced with and without 1 μg/ml of tetracycline for 24 
hours. The cells were harvested and incubated with PGC/antibody conjugate beads. The lysates, 
flow through and IP pull downs were analyzed with HA3F10 antibody.  
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Figure 11.  Immunofluorescent detection of exogenous proteins expressed in Flp-In U2OS 
cell lines. Flp-In U2OS cells expressing wt-CK2α-HA (A), as-CK2α-HA (B) and as-CK2α-HA 
(C) were cultured in the absence (-) or presence (+) of 1 μg/mL of tetracycline for 24 hours. The 
cells were then fixed and stained with a FITC-conjugated anti-HA monoclonal antibody, as 
previously described in the materials and methods. Cells were also stained with a Hoechst 33258 
DAPI stain in order to visualize cell nuclei. A phase contrast image has also been included. The 
images were obtained on Nikon Eclipse microscope at 20X magnification. Identical fields were 
imaged in the absence (-) or presence (+) of tetracycline for each cell line.  
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2.2.8 Assessment of the ability of as-CK2 to phosphorylate cellular substrates in cell lysate 
 
Mass spectrometry-based proteomics can be used to give the quantitative state of a 
proteome, and thereby provides details of the biochemical state of the relevant cell and 
tissue in differential biological conditions (Schubert et al, 2017). SILAC labelling is one 
the strategies used for quantitative proteomics. SILAC labelling involves the labeling of 
arginine and lysine amino acids with heavy 13C or 15N stable isotopes (Ong and Mann, 
2006). SILAC labelling strategy allows differentially treated biological conditions to be 
mixed in 1:1 ratio and digested together, as the trypsin cleave after C-terminus of arginine 
and lysine. During LC-MS/MS analysis the heavy and light peptides elute together during 
chromatographic separation. These eluted peptides are distinguishable only due to 
differences in their mass because of the heavy label of arginine or lysine.  
 
The stable cell lines were adopted in SILAC media for 7 passages, so that the proteins 
were isotopically labelled to greater than 95%, as it is the standard conditions required in 
SILAC labelling (Ong and Mann, 2006). Proline was supplemented in the media to avoid 
the metabolic conversation of Arginine to Proline. The incorporation efficiency calculated 
was 96%. To assess the utility of as-CK2 to identify direct substrates of CK2 within the 
complexity of the cellular environment, we used SILAC labelling approach for proteomic 
analysis of the substrates thio-phosphorylated by the as-CK2α and α’. The Stable cell 
lines, as-CK2α (Lys8; Arg10), wt-CK2α (Lys4; Arg6) and U2OS-Flp-In parental cells 
(Lys0; Arg0) were induced with tetracycline for 24 hours in their respective SILAC 
media. The lysates were supplemented with ATP and 2peATPγS in 1:1 ratio. The 
workflow is depicted in Figure 12. After performing the thiophosphorylation reaction 
small amount of sample from each reaction was alkylated by PNBM and analyzed by 
western blot analysis (Figure 13). An additional control kinase reaction was done in 
U2OS-parental cells without addition of 2peATPγS. The thiophosphorylation observed in 
the sample without 2peATPγS addition was considered as background. The U2OS-Flp-In 
parental cells and wt-CK2α showed similar intensities as background showing that the 
2peATPγS utilization is minimal in these samples. In contrast, as-CK2α 
thiophosphorylated more proteins and utilized 2peATPγS more efficiently as seen on the 
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blots using thiophosho-ester antibody (Figure 13A, last lane). A comparison between the 
expression levels of as-CK2α and wt-CK2α was detected using HA3F10 and CK2α 
antibody (Figure 13A).  On the other hand, as-CK2α’ showed similar utilization of 
2peATPγS to the wt-CK2α’and the U2OS-parental cells, as seen on the blots using 
thiophosho-ester antibody (Figure 13B). The expression level of both as-CK2α’and wt-
CK2α’ was really low and all the data suggests that this utilization is similar to the 
background.  
After the kinase reaction with 2peATPγS, all three labelled cell lines were mixed in 1:1:1 
ratio, precipitated (methanol/chloroform method), digested with trypsin and the 
thiopeptides were captured using Iodoacetyl beads. To elute thiopeptides, beads were 
treated with oxone.  The oxone treatment elutes these thiopeptides in the form of 
phosphopetides, since the thiophosphoryl sulfur atom is replaced with oxygen after 
hydrolysis of sulfur-phosphorus bond (Han et al, 2016). The experiments were performed 
in nine biological replicates. The samples were analyzed using nano LC-MS/MS and the 
identification of the peptides were done using PEAKS 8.  
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Figure 12: Proteomic workflow for the identification of CK2 substrates: The SILAC labelled 
cells wt-CK2α and α’ (Medium), as-CK2α and α’ (Heavy) and U2OS-parental cell line (Light) 
were supplemented with 2peATPγS for thiophosphorylation reaction to take place. The lysates of 
all three labels were combined in 1:1:1 ratio and digested with trypsin. The peptides were added 
with iodocetyl beads which capture the thiophosphorylated peptides only. The thio-peptides were 
run through LC-MS/MS mass spectrometer for the identification of these peptides. The raw data 
was analyzed through Peaks8 data analysis software. The peptides unique in as-CK2 were 
considered as CK2 substrates.  
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Figure 13: Thiophoshorylation reaction and utilization of 2peATPγS by stable cell lines. Kinase 
assays were performed by supplementing 2peATPγS to stable cell lines wt-CK2α (Medium), as-
CK2α (Heavy) and U20S-parental cell (Light) (A). wt-CK2α’ (Medium), as-CK2α’ (Heavy) and 
U20S-parental cell (Light) (B). After the kinase reaction, samples were alkylated by treatment 
with PNBM, and thiophosphorylation was detected by immunoblotting with an anti-thiophosphate 
ester antibody. An additional control was added in which reaction was not supplemented with 
2peATPγS, but was alkylated to check the background. The expression of exogenous kinase was 
detected by HA3F10 antibody. The expression of the total Ck2 kinase was detected by CK2α 
antibody. 
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2.2.9 Data analysis and identification of CK2 substrates  
 
Peptides identification from tandem mass spectrometry (MS/MS) data is a central task in 
proteomics (Ma et al, 2003). Peaks studio is data analysis and statistics package for 
analyzing LC-MSMS data. MS/MS spectra are analyzed for identification of peptides, 
and the sequences of amino acids generated are used to identify the protein from the data 
bases. The PTM’s are also determined by calculating the confidence of the modification 
site (Ascore values). This Ascore is the calculation of ambiguity score as -10 × log10 P 
<0.005 and higher the Ascore there is more confidence in the modification (Ma et al, 
2003). 
The proteins only found in as-CK2α or α’ were unique to considered as CK2 substrates 
and the other were considered as background. A total of 80 unique 
phosphopeptides/thiophosphopeptides were identified based on FDR 1% (-10log P ≥ 
18.59) in both as-CK2α and α’. Unique peptides only present in heavy label are indicated 
in black font (Table 1). Unique peptides present in light and/or medium label in addition 
to heavy label are indicated in red font. Due to a high degree of irreproducibility across 
nine analyzed replicates, additional restrictions were applied using phosphorylation sites' 
Ascore values. Those phosphorylation sites that contain an Ascore <19 (less than 99% 
site confidence) are considered ambiguous; however, phosphorylation sites with an 
Ascore from 10 - 19 (90% - 99% site confidence) are reported in the table along with the 
phosphorylation sites having an Ascore ≥ 19 (≥ 99% site confidence). Phosphorylation 
sites with an Ascore ≥ 19 (≥ 99% site confidence) are indicated in bold, while 
phosphorylation sites with an Ascore between 15 - 19 (97% - 99% site confidence) and 
10 -15 (90% - 97% site confidence) are indicated as non-bold and highlighted in grey 
respectively. The unique thiophosphorylated peptides found in as-CK2α’ were not 
according to the Ascore ≥ 19 (so were not considered), this could be due to the low level 
of expression of the exogenous as-CK2 α’, which is was not able to utilize the 2peATPγS. 
In summary, 27 non-redundant phosphorylation sites were identified at ≥ 97% site 
confidence, of which 24 phosphorylation sites were identified at ≥ 99% site confidence 
(Table 2). These 24 proteins are considered as CK2α substrates after having a strict 
scoring system. The biological functions of these proteins are given in detail in table 3. 
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Protein Accession Phosphoeptide Mass -10lgP AScore 
O43818|U3IP2_HUMAN G(+42.01)K(+8.01)PAS(+79.97)GAGAGAGAGKRR 1597.7928 20.7 S5:1000.00 
O95218|ZRAB2_HUMAN EVEDK(+8.01)ES(+79.97)EGEEEDEDEDLSK(+8.01) 2434.9243 21.8 S7:54.40 
P15880|RS2_HUMAN LLMMAGIDDCY(+79.97)TSAR(+10.01) 1748.7212 21.47 Y11:40.00 
P23528|COF1_HUMAN A(+42.01)S(+79.97)GVAVSDGVIK(+8.01) 1231.594 35.56 S2:86.57 
P31943|HNRH1_HUMAN DLNYCFS(+79.97)GMSDHR(+10.01) 1633.593 21.51 S7:22.45 
P38646|GRP75_HUMAN AK(+8.01)NAVIT(+79.97)VPAYFNDSQR 1980.955 29.14 T7:86.34 
P43243|MATR3_HUMAN DETDLANLGDVAS(+79.97)DGKK(+8.01)EPSDK(+8.01) 3157.4158 18.87 S21:29.98 
P48681|NEST_HUMAN IPGEGHPES(+79.97)PEPK(+8.01) 1460.6428 36.3 S9:1000.00 
P48681|NEST_HUMAN IPGEGHPES(+79.97)PEPK(+8.01)EQR(+10.01) 1883.8533 30.56 S9:1000.00 
P50914|RL14_HUMAN APGT(+79.97)KGT(+79.97)AAAAAAAAAAK(+8.01) 1636.7466 21.42 T4:1000.00;T7:1000.00 
P83369|LSM11_HUMAN ARGAAAGSGVPAAPGPSGR(+10.01)T(+79.97)R(+6.02) 1958.9769 20.84 T20:20.70 
Q01970|PLCB3_HUMAN KR(+10.01)HRPS(+79.97)AGGPDSAGR 1637.7775 26.81 S6:90.89 
Q07020|RL18_HUMAN ALDS(+79.97)PK(+8.01)GCGTVLLSGPR(+6.02) 1763.8827 18.9 S4:23.15 
Q14315|FLNC_HUMAN VRAS(+79.97)GPGLER(+10.01) 1130.5472 19.61 S4:1000.00 
Q14676|MDC1_HUMAN LLLAEDS(+79.97)EEEVDFLSER(+10.01) 2082.9272 36.89 S7:113.22 
Q15019|SEPT2_HUMAN IYHLPDAES(+79.97)DEDEDFK(+8.01)EQTR(+10.01) 2534.0605 28.47 S9:37.29 
Q2M2I5|K1C24_HUMAN T(+42.01)(+79.97)K(+8.01)CQNAEYKQ(+.98)LLDIK 1924.9097 23.01 T1:27.25 
Q86V81|THOC4_HUMAN G(+42.01)AGGFGGGGGT(+79.97)RR(+10.01) 1237.5228 19.87 T11:1000.00 
Q8IWI9|MGAP_HUMAN ES(+79.97)K(+8.01)VMPTLAPVVAK(+8.01) 1564.827 20.92 S2:23.70 
Q8WUW1|BRK1_HUMAN IADFLNSFDMS(+79.97)CR(+10.01) 1607.6389 33.71 S11:44.28 
Q8WUW1|BRK1_HUMAN K(+8.01)IADFLNSFDMS(+79.97)CR(+10.01) 1743.748 29.09 S12:52.86 
Q9BRR0|ZKSC3_HUMAN AFIGS(+79.97)SALVIHQR(+10.01) 1487.7524 24.48 S5:20.92 
Q9BY77|PDIP3_HUMAN NGNVIT(+79.97)SDQ(+.98)PILLR(+10.01) 1629.8003 18.59 T6:40.00 
Q9NQ55|SSF1_HUMAN VGGS(+79.97)DEEASGIPSR(+10.01) 1449.6012 32.46 S4:51.00 
O00555|CAC1A_HUMAN NNKLATAESAAPHGSLGHAGLPQ(+.98)S(+79.97)PAK(+8.01) 2712.311 36.09 S24:18.04 
P04792|HSPB1_HUMAN QLS(+79.97)SGVSEIR(+10.01) 1164.5415 41.29 S3:16.90 
Q68DK7|MSL1_HUMAN K(+42.01)(+8.01)S(+79.97)PLGGGGGSGASSQAACLK 1861.8484 21.85 S2:17.65 
          
Table 2: Proteins with Ascore ≥ 19 (≥ 99% site confidence) 
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2.3 Conclusion and future prospect 
 
In conclusion, we have generated an analog-sensitive CK2α and α’ kinase by mutating 
the gatekeeper/bulky residue to glycine to enlarge the nucleotide-binding pocket. The 
mutants, as-CK2α and α’ efficiently utilize a bulky ATP analog, 2peATPγS to 
phosphorylate substrates. Phosphorylation of proteins by as-CK2α and α’ using 
2peATPγS in cell lysate illustrates the specificity and sensitivity of the as-CK2 strategy 
as a novel molecular tool to identify direct substrates and, finally, to study the cellular 
roles of CK2. A common limitation in other approaches is their inability to confidently 
identify direct substrates of CK2 on a large-scale. The strength of the as-CK2 strategy is 
the enlarged nucleotide-binding pocket that uniquely and efficiently utilizes 2peATP to 
phosphorylate cellular substrates of CK2. The advantage in the use of 2peATP lies with 
an additional tag on the γ-phosphate to specifically label direct substrates of CK2. Thus, 
the labeled substrates could be captured with affinity enrichment, and can be identified 
by mass spectrometry.  We validated our strategy by thiophosphorylating proteins in cell 
lysate, and used thiopeptide capture strategy by using iodoacetyl beads to capture the 
digested thiopeptides and identified them using mass spectrometry. The data was analyzed 
using Peaks package to identify thiophospho peptides. Unique thiophosphorylated 
peptides generated by the as-CK2 catalytic subunits were considered as potential CK2 
substrates. A stringent scoring system was used to have more confidence in identifying 
the substrates. The peptides which had an Ascore ≥ 19 (≥ 99% site confidence) were 
considered as substrates of CK2.  
 
This approach further outlines a framework that can be used in future to further improve 
and develop this approach to globally identify direct substrates of CK2 and further 
discover the cellular roles of CK2 and strengthen the foundation for future drug 
development.  To further explore the cellular roles of CK2, mouse models and mammalian 
cell lines could be established which have the endogenous CK2 gene replaced with the 
as-CK2 allele. This would prove to be extremely useful in identifying more bona fide 
substrates of CK2, as this would eliminate the role of wt-CK2 endogenous interference of 
CK2. One approach to mutate the endogenous CK2 catalytic subunits, could be to use 
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CRISPR/Cas genome editing technique.  As seen in figure 3A and 3B that as-CK2α and 
α’ can slightly utilize ATP, this could be applied when gatekeeper mutation is introduced 
endogenously. There would be a decrease in fold change of phosphopetides in as-CK2 
samples compared to wt-CK2, as as-CK2 has less affinity for ATP. The SILAC approach 
could then be used for quantifying the phosphoproteome of as-CK2 endogenous mutant 
and wt-CK2. This approach would give global prospective of bona fide substrates of CK2 
kinase. Moreover, these quantitative phosphoproteomic results may be compared with 
those obtained by using different known competitive inhibitors of CK2, like TBBz or 
CX4946. Since the structural studies have shown that F113 residue in CK2 active site 
interacts with the TBBz inhibitor (Battistutta et al, 2001; Battistutta et al, 2007) the 
mutation of this hydrophobic residue, as seen in figure 1, would open the active site and 
the interaction of inhibitor would be less strong, in this way it makes less inhibition. This 
would allow the quantification of treated samples compared to control.  
The other approach to complement this chemical genetic approach is to use of PP1 (4-
Amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine) analogue inhibitors 
(Bishop et al, 1999). Originally PP1 inhibitors had been developed to inhibit Src tyrosine 
kinases (Hanke et al, 1996). The analogues of PP1 have bulky chains which would only 
allow these inhibitors to attach to as-CK2 protein as they have larger ATP binding site, 
this would allow to use quantitative phosphoproteomic approach to identify substrates of 
CK2. In summary, using the above-mentioned approaches, will increase identification the 
number of bona fide CK2 substrates and further help in studying the kinase-substrate 
relationships of CK2. 
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